AR119088A1 - Compuestos de 2,3,5-pirazolo[1,5-a]pirimidina trisustituida - Google Patents
Compuestos de 2,3,5-pirazolo[1,5-a]pirimidina trisustituidaInfo
- Publication number
- AR119088A1 AR119088A1 ARP200101579A ARP200101579A AR119088A1 AR 119088 A1 AR119088 A1 AR 119088A1 AR P200101579 A ARP200101579 A AR P200101579A AR P200101579 A ARP200101579 A AR P200101579A AR 119088 A1 AR119088 A1 AR 119088A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- independently selected
- co2h
- po3h2
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 12
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 10
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical group 0.000 abstract 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 2
- -1 C1−6 Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0636—Irradiating the whole body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857148P | 2019-06-04 | 2019-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119088A1 true AR119088A1 (es) | 2021-11-24 |
Family
ID=73652950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101579A AR119088A1 (es) | 2019-06-04 | 2020-06-04 | Compuestos de 2,3,5-pirazolo[1,5-a]pirimidina trisustituida |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12410170B2 (enExample) |
| EP (1) | EP3980010A4 (enExample) |
| JP (1) | JP7665534B2 (enExample) |
| KR (1) | KR20220047247A (enExample) |
| CN (1) | CN114206332B (enExample) |
| AR (1) | AR119088A1 (enExample) |
| AU (1) | AU2020288610A1 (enExample) |
| CA (1) | CA3142712A1 (enExample) |
| TW (1) | TWI857071B (enExample) |
| UY (1) | UY38742A (enExample) |
| WO (1) | WO2020247496A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| EP4326260A4 (en) * | 2021-04-20 | 2025-05-28 | The Regents of The University of Michigan | Pi3k inhibitors, nanoformulations, and uses thereof |
| WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| EP4341261A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl compounds |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| CN119072476A (zh) * | 2022-03-02 | 2024-12-03 | 上海海雁医药科技有限公司 | 六元芳环并吡咯酮衍生物、其药物组合物及应用 |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119768404A (zh) * | 2022-09-01 | 2025-04-04 | 上海海雁医药科技有限公司 | 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用 |
| CN119768155A (zh) | 2022-09-14 | 2025-04-04 | 艾库斯生物科学有限公司 | 依曲地南的分散体 |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| US20240180947A1 (en) | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025146216A1 (zh) * | 2024-01-05 | 2025-07-10 | 成都赜灵生物医药科技有限公司 | 六并五氮杂环酰胺类化合物及其用途 |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| US20090029997A1 (en) | 2006-01-23 | 2009-01-29 | Laboratoires Serono Sa | Thiazole Derivatives and Use Thereof |
| BRPI0716239A2 (pt) | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| AU2008328882A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as PI3K inhibitors |
| GB0812309D0 (en) | 2008-07-03 | 2008-08-13 | Ucb Pharma Sa | Therapeutic agents |
| AR073524A1 (es) | 2008-09-30 | 2010-11-10 | Exelixis Inc | Piridopirimidinonas inhibidores de pi3k a y m tor |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| KR101758046B1 (ko) | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| SG11201602265PA (en) | 2013-09-25 | 2016-04-28 | Vertex Pharma | A selective inhibitor of phosphatidylinositol 3-kinase-gamma |
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| MX382033B (es) * | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| ES2802202T3 (es) | 2014-09-03 | 2021-01-15 | Rhizen Pharmaceuticals S A | Método de tratamiento y composiciones que comprenden un inhibidor dual de la quinasa PI3K delta-gama y un corticoesteroide |
| EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| PT3371190T (pt) | 2015-11-06 | 2022-07-08 | Incyte Corp | Compostos heterocíclicos como inibidores de pi3k-gamma |
| EP3426652B1 (en) | 2016-03-10 | 2021-12-01 | Astrazeneca AB | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
| MA46268B1 (fr) | 2016-09-22 | 2020-08-31 | Astrazeneca Ab | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma |
| CN108017641B (zh) | 2016-11-02 | 2021-01-05 | 深圳铂立健医药有限公司 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
-
2020
- 2020-06-03 CN CN202080053447.9A patent/CN114206332B/zh active Active
- 2020-06-03 WO PCT/US2020/035920 patent/WO2020247496A1/en not_active Ceased
- 2020-06-03 JP JP2021572048A patent/JP7665534B2/ja active Active
- 2020-06-03 KR KR1020227000091A patent/KR20220047247A/ko not_active Ceased
- 2020-06-03 US US17/615,550 patent/US12410170B2/en active Active
- 2020-06-03 CA CA3142712A patent/CA3142712A1/en active Pending
- 2020-06-03 AU AU2020288610A patent/AU2020288610A1/en not_active Abandoned
- 2020-06-03 EP EP20818646.0A patent/EP3980010A4/en active Pending
- 2020-06-04 UY UY0001038742A patent/UY38742A/es not_active Application Discontinuation
- 2020-06-04 TW TW109118850A patent/TWI857071B/zh active
- 2020-06-04 AR ARP200101579A patent/AR119088A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI857071B (zh) | 2024-10-01 |
| JP7665534B2 (ja) | 2025-04-21 |
| UY38742A (es) | 2020-12-31 |
| CA3142712A1 (en) | 2020-12-10 |
| CN114206332A (zh) | 2022-03-18 |
| TW202110850A (zh) | 2021-03-16 |
| US12410170B2 (en) | 2025-09-09 |
| JP2022535120A (ja) | 2022-08-04 |
| EP3980010A1 (en) | 2022-04-13 |
| KR20220047247A (ko) | 2022-04-15 |
| AU2020288610A1 (en) | 2022-01-27 |
| WO2020247496A1 (en) | 2020-12-10 |
| US20230024302A1 (en) | 2023-01-26 |
| CN114206332B (zh) | 2024-08-23 |
| EP3980010A4 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119088A1 (es) | Compuestos de 2,3,5-pirazolo[1,5-a]pirimidina trisustituida | |
| AR120684A1 (es) | INHIBIDORES DE HIF-2a | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR117102A1 (es) | Inhibidores de arg1 y/o arg2 | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR114948A1 (es) | Compuestos de benzamida | |
| PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| AR089796A1 (es) | COMPUESTOS b-LACTAMICOS SUSTITUIDOS CON AMIDINA, SU PREPARACION Y USO | |
| AR107293A1 (es) | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g | |
| AR091022A1 (es) | Inhibidores del nampt | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR120652A1 (es) | Antagonistas de sstr5 | |
| EA201791816A1 (ru) | Ингибиторы kv1.3 и их применение в медицине | |
| AR110349A1 (es) | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga | |
| AR098723A1 (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
| AR125608A1 (es) | Novedosos compuestos útiles como agonistas de sting y sus usos | |
| AR117989A1 (es) | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico | |
| AR113935A1 (es) | Compuesto de 1h-pirrolo[3,2-b]piridin-2-ilo, composición farmacéutica que lo comprende y su uso para fabricar un medicamento | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
| AR113980A1 (es) | Método para mejorar la biodisponibilidad oral de una droga | |
| ES2667276T3 (es) | Derivados de sulfonilindol y método para prepararlos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |